ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.
A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.
